REGENERON PHARMACEUTICALS, INC. Net Income (Loss) Attributable to Parent, Diluted
REGENERON PHARMACEUTICALS, INC. (REGN) reported Net Income (Loss) Attributable to Parent, Diluted of $2.44 billion for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-07.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2019-02-07
- REGENERON PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for fiscal 2018 was $2.44B, a 103.95% increase from fiscal 2017.
- REGENERON PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for fiscal 2017 was $1.20B, a 33.78% increase from fiscal 2016.
- REGENERON PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for fiscal 2016 was $895.90M, a 40.85% increase from fiscal 2015.
- REGENERON PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for fiscal 2015 was $636.06M, a 88.11% increase from fiscal 2014.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 12 month | Net Income (Loss) Attributable to Parent, Diluted 12 month as first filed |
|---|---|---|
| 2018-12-31 | $2.44B 10-K · filed 2019-02-07 | |
| 2017-12-31 | $1.20B 10-K · filed 2019-02-07 | $1.20B 10-K · filed 2018-02-08 |
| 2016-12-31 | $895.90M 10-K · filed 2019-02-07 | $895.92M 10-K · filed 2017-02-09 |
| 2015-12-31 | $636.06M 10-K · filed 2018-02-08 | |
| 2014-12-31 | $338.13M 10-K · filed 2017-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |